Skip to main content

Advertisement

Table 4 Post-treatment changes in CRP, ESR, and Igs

From: Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

  Post-treatment change from baseline (mean ± standard deviation)
Parameters 6 weeks 10 weeks 18 weeks 32 weeks
  n = 13 n = 13 n = 12 n = 10
CRP 0.42 ± 1.39 -0.02 ± 0.33 0.19 ± 0.60 0.03 ± 0.22
ESR 1.3 ± 15.0 1.5 ± 11.0 -0.9 ± 7.7 -0.3 ± 11.6
  n = 15 n = 13 n = 13 n = 9
IgG 29.7 ± 249.6 -31 ± 379.6 7.1 ± 313.5 -120.8 ± 363.3
IgA 1.1 ± 24.4 7.8 ± 46.9 -1.2 ± 59 -3.8 ± 62.4
IgM -14.9 ± 25.3 -9.6 ± 28.3 -15.0 ± 32.8 -2.3 ± 34.8
  1. None of the changes from baseline in the above parameters was statistically significant. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Ig, immunoglobulin.